Diagnostic Value of Targeted Next-generation Sequencing in Pulmonary Mycobacterial Infections

Abstract

Objective

This study aimed to explore the diagnostic value of novel technique-targeted next-generation sequencing (tNGS) of bronchoalveolar lavage fluid (BALF) in pulmonary mycobacterial infections.

Methods

This retrospective study was conducted on patients who underwent bronchoscopy and tNGS, smear microscopy, and mycobacterial culture of BALF. Patients with positive Mycobacterium tuberculosis (MTB) culture or GeneXpert results were classified into the tuberculosis case group. Those diagnosed with nontuberculous mycobacteria (NTM)-pulmonary disease (NTM-PD) composed the case group of NTM-PD patients. The control group comprised patients without tuberculosis or NTM-PD. Sensitivity, specificity, and receiver operating characteristic (ROC) curves were used to evaluate the diagnostic performance.

Results

For tuberculosis patients with positive mycobacterial culture results, the areas under the ROC curves (AUCs) for tNGS, GeneXpert, and smear microscopy were 0.975 (95% CI: 0.935, 1.000), 0.925 (95% CI: 0.859, 0.991), and 0.675 (95% CI: 0.563, 0.787), respectively. For tuberculosis patients with positive GeneXpert results, the AUCs of tNGS, culture, and smear microscopy were 0.970 (95% CI: 0.931, 1.000), 0.850 (95% CI: 0.770, 0.930), and 0.680 (95% CI: 0.579, 0.781), respectively. For NTM-PD, the AUCs of tNGS, culture, and smear-positive but GeneXpert-negative results were 0.987 (95% CI: 0.967, 1.000), 0.750 (95% CI: 0.622, 0.878), and 0.615 (95% CI: 0.479, 0.752), respectively. The sensitivity and specificity of tNGS in NTM-PD patients were 100% and 97.5%, respectively.

Conclusion

tNGS demonstrated superior diagnostic efficacy in mycobacterial infection, indicating its potential for clinical application.

References

[1] Ratnatunga CN, Lutzky VP, Kupz A, et al.. The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front Immunol, 2020, 11: 303

[2] Cosma CL, Sherman DR, Ramakrishnan L. The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol, 2003, 57: 641-676

[3] Johansen MD, Herrmann JL, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol, 2020, 18(7): 392-407

[4] Reid MJA, Arinaminpathy N, Bloom A, et al.. Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, 2019, 393(10178): 1331-1384

[5] Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO

[6] Park IK, Olivier KN. Nontuberculous mycobacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin Respir Crit Care Med, 2015, 36(2): 217-224

[7] Daley CL, Iaccarino JM, Lange C, et al.. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis, 2020, 71(4): 905-913

[8] van Ingen J. Microbiological diagnosis of nontuberculous mycobacterial pulmonary disease. Clin Chest Med, 2015, 36(1): 43-54

[9] Bethencourt Mirabal A, Ferrer G. Lung Nontuberculous Mycobacterial Infections. StatPearls, 2023 Treasure Island (FL) StatPearls Publishing

[10] Suresh P, Kumar A, Biswas R, et al.. Epidemiology of Nontuberculous Mycobacterial Infection in Tuberculosis Suspects. Am J Trop Med Hyg, 2021, 105(5): 1335-1338

[11] Luetkemeyer AF, Kendall MA, Wu X, et al.. Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol, 2014, 52(4): 1052-1059

[12] Kim TC, Blackman RS, Heatwole KM, et al.. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Prevalence and significance of negative smears pretreatment and positive smears post-treatment. Am Rev Respir Dis, 1984, 129(2): 264-268

[13] Gopalaswamy R, Shanmugam S, Mondal R, et al.. Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment. J Biomed Sci, 2020, 27(1): 74

[14] Azadi D, Motallebirad T, Ghaffari K, et al.. Mycobacteriosis and Tuberculosis: Laboratory Diagnosis. Open Microbiol J, 2018, 12: 41-58

[15] Stephenson D, Perry A, Appleby MR, et al.. An evaluation of methods for the isolation of nontuberculous mycobacteria from patients with cystic fibrosis, bronchiectasis and patients assessed for lung transplantation. BMC Pulm Med, 2019, 19(1): 19

[16] Use of Xpert MTB/RIF and Xpert MTB/RIF Ultra on GeneXpert 10-colour instruments: WHO policy statement. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO

[17] Blauwkamp TA, Thair S, Rosen MJ, et al.. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol, 2019, 4(4): 663-674

[18] Pendleton KM, Erb-Downward JR, Bao Y, et al.. Rapid Pathogen Identification in Bacterial Pneumonia Using Real-Time Metagenomics. Am J Respir Crit Care Med, 2017, 196(12): 1610-1612

[19] Simner PJ, Miller HB, Breitwieser FP, et al.. Development and Optimization of Metagenomic Next-Generation Sequencing Methods for Cerebrospinal Fluid Diagnostics. J Clin Microbiol, 2018, 56(9): e00472-e00518

[20] Flurin L, Wolf MJ, Mutchler MM, et al.. Targeted Metagenomic Sequencing-based Approach Applied to 2146 Tissue and Body Fluid Samples in Routine Clinical Practice. Clin Infect Dis, 2022, 75(10): 1800-1808

[21] Huang C, Huang Y, Wang Z, et al.. Multiplex PCR-based next generation sequencing as a novel, targeted and accurate molecular approach for periprosthetic joint infection diagnosis. Front Microbiol, 2023, 14: 1181348

[22] Wu X, Liang R, Xiao Y, et al.. Application of targeted next generation sequencing technology in the diagnosis of Mycobacterium Tuberculosis and first line drugs resistance directly from cell-free DNA of bronchoalveolar lavage fluid. J Infect, 2023, 86(4): 399-401

[23] Poulsen SH, Søgaard KK, Fuursted K, et al.. Evaluating the diagnostic accuracy and clinical utility of 16S and 18S rRNA gene targeted next-generation sequencing based on five years of clinical experience. Infect Dis (Lond), 2023, 55(11): 767-775

[24] Li S, Tong J, Liu Y, et al.. Targeted next generation sequencing is comparable with metagenomic next generation sequencing in adults with pneumonia for pathogenic microorganism detection. J Infect, 2022, 85(5): e127-e129

[25] Diagnosis for pulmonary tuberculosis. The health industry standard of the People’s Republic of China (WS 288–2017). National Health and Family Planning Commission of the People’s Republic of China, 2017-11-09 [Accessed 2021-06-30]. Available from: http://www.nhc.gov.cn/wjw/s9491/201712/a452586fd21d4018b0ebc00b89c06254.shtml

[26] Chinese Medical Association Tuberculosis Branch. Guidelines for the Diagnosis and Treatment of Non-Tuberculous Mycobacterial Diseases (2020 Edition). Chi J Tuberc Respir Dis(Chinese), 2020, 43(11): 918-946

[27] Peng Z, Zhou J, Tian L. Pathogenic characteristics of sputum and bronchoalveolar lavage fluid samples from patients with lower respiratory tract infection in a large teaching hospital in China: a retrospective study. BMC Pulm Med, 2020, 20(1): 233

[28] Bodal VK, Bal MS, Bhagat S, et al.. Fluorescent microscopy and Ziehl-Neelsen staining of bronchoalveolar lavage, bronchial washings, bronchoscopic brushing and post bronchoscopic sputum along with cytological examination in cases of suspected tuberculosis. Indian J Pathol Microbiol, 2015, 58(4): 443-447

[29] Aber VR, Allen BW, Mitchison DA, et al.. Quality control in tuberculosis bacteriology. 1. Laboratory studies on isolated positive cultures and the efficiency of direct smear examination. Tubercle, 1980, 61(3): 123-133

[30] Levy H, Feldman C, Sacho H, et al.. A reevaluation of sputum microscopy and culture in the diagnosis of pulmonary tuberculosis. Chest, 1989, 95(6): 1193-1197

[31] Dutt AK, Stead WW. Smear-negative pulmonary tuberculosis. Semin Respir Infect, 1994, 9(2): 113-119

[32] Deng Y, Duan YF, Gao SP, et al.. Comparison of LAMP, GeneXpert, Mycobacterial Culture, Smear Microscopy, TSPOT.TB, TBAg/PHA Ratio for Diagnosis of Pulmonary Tuberculosis. Curr Med Sci, 2021, 41(5): 1023-1028

[33] Khalil KF, Butt T. Diagnostic yield of Bronchoalveolar Lavage gene Xpert in smear-negative and sputum-scarce pulmonary tuberculosis. J Coll Physicians Surg Pak, 2015, 25(2): 115-118

[34] Sharma JB, Dharmendra S, Jain S, et al.. Evaluation of Gene Xpert as compared to conventional methods in diagnosis of Female Genital Tuberculosis. Eur J Obstet Gynecol Reprod Biol, 2020, 255: 247-252

[35] Lu Y, Zhu Y, Shen N, et al.. Evaluating the diagnostic accuracy of the Xpert MTB/RIF assay on bronchoalveolar lavage fluid: A retrospective study. Int J Infect Dis, 2018, 71: 14-19

[36] Wu SH, Xiao YX, Hsiao HC, et al.. Development and Assessment of a Novel Whole-Gene-Based Targeted Next-Generation Sequencing Assay for Detecting the Susceptibility of Mycobacterium tuberculosis to 14 Drugs. Microbiol Spectr, 2022, 10(6): e0260522

[37] Cabibbe AM, Spitaleri A, Battaglia S, et al.. Application of Targeted Next-Generation Sequencing Assay on a Portable Sequencing Platform for Culture-Free Detection of Drug-Resistant Tuberculosis from Clinical Samples. J Clin Microbiol, 2020, 58(10): e00632-e00720

[38] Murphy SG, Smith C, Lapierre P, et al.. Direct detection of drug-resistant Mycobacterium tuberculosis using targeted next generation sequencing. Front Public Health, 2023, 11: 1206056

[39] Sibandze DB, Kay A, Dreyer V, et al.. Rapid molecular diagnostics of tuberculosis resistance by targeted stool sequencing. Genome Med, 2022, 14(1): 52

[40] Arora D, Dhanashree B. Utility of smear microscopy and GeneXpert for the detection of Mycobacterium tuberculosis in clinical samples. Germs, 2020, 10(2): 81-87

[41] Fida M, Khalil S, Abu Saleh O, et al.. Diagnostic Value of 16S Ribosomal RNA Gene Polymerase Chain Reaction/Sanger Sequencing in Clinical Practice. Clin Infect Dis, 2021, 73(6): 961-968

[42] Azad MA, Wolf MJ, Strasburg AP, et al.. Comparison of the BioFire Joint Infection Panel to 16S Ribosomal RNA Gene-Based Targeted Metagenomic Sequencing for Testing Synovial Fluid from Patients with Knee Arthroplasty Failure. J Clin Microbiol, 2022, 60(12): e0112622

[43] Hilt EE, Ferrieri P. Next Generation and Other Sequencing Technologies in Diagnostic Microbiology and Infectious Diseases. Genes (Basel), 2022, 13(9): 1566

[44] Chiu CY, Miller SA. Clinical metagenomics. Nat Rev Genet, 2019, 20(6): 341-355

[45] The use of next-generation sequencing for the surveillance of drug-resistant tuberculosis: an implementation manual. Geneva: World Health Organization, 2023. Licence: CC BY-NC-SA 3.0 IGO

[46] Zignol M, Cabibbe AM, Dean AS, et al.. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infect Dis, 2018, 18(6): 675-683

[47] Expert Group on Consensus for High-throughput Sequencing. Expert consensus on the application of high-throughput sequencing technology in the diagnosis of mycobacterial diseases. Chin J Infect Dis (Chinese), 2023, 41(3): 175-182

[48] Griffith DE, Aksamit T, Brown-Elliott BA, et al.. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007, 175(4): 367-416

[49] Wang S, Xing L. Metagenomic next-generation sequencing assistance in identifying non-tuberculous mycobacterial infections. Front Cell Infect Microbiol, 2023, 13: 1253020

[50] Ren HQ, Zhao Q, Yang W, et al. Connective Tissue Disease-Associated Pulmonary Interstitial Fibrosis with Mycobacterium Paraintracellulare Infection: a Case Report. Clin Lab, 2023,69(5)

[51] Nie CX, Zhang JB, Ji HL, et al. Multiple Postoperative Lung Infections after Thymoma Surgery Diagnosed as Nontuberculous Mycobacterial Infection. Clin Lab, 2024,70(8)

[52] Yu L, Wan H, Shi J, et al.. Disseminated Mycobacterium thermoresistibile Infection presented with Lymphadenectasis in an AIDS patient: case report and review of literature. BMC Infect Dis, 2023, 23(1): 769